Publications
198
Citations
3,755
Est. group size
—
Recurring co-author estimate
Active years
29
Publishing since 1998
This researcher focuses on multiple myeloma, a cancer of the plasma cells in the bone marrow, with an emphasis on developing and testing new treatments. Much of the work involves clinical trials of immunotherapies, including bispecific antibodies and CAR T-cell therapy, that harness the immune system to fight the disease in patients whose cancer has returned or resisted prior treatment. Additional work covers treatment guidelines, cost-effectiveness of therapies, and disparities in access to care.
Publication activity has grown substantially over the past decade, with a notable surge in recent years (37 in 2023 and 46 in 2025).
Generated by claude-opus-4-8 from public bibliographic data · Jul 11, 2026
- Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-Cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study
Clinical Cancer Research · 2026
- Talquetamab with pomalidomide in patients with relapsed/refractory multiple myeloma (RRMM): Updated safety/efficacy from MonumenTAL-2
Ghent University Academic Bibliography (Ghent University) · 2026
- NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025
Journal of the National Comprehensive Cancer Network · 2025
- Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses
Clinical Lymphoma Myeloma & Leukemia · 2025
- Safety and efficacy of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma: Results from the phase 1b MagnetisMM-30 trial
Blood · 2025
- Linvoseltamab in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) in the LINKER-MM1 Study: Longer Follow-up and Subgroup Analyses
Clinical Lymphoma Myeloma & Leukemia · 2025
- Patient-Reported Quality of Life with Linvoseltamab in Triple-Class Exposed Patients with Relapsed/Refractory Multiple Myeloma: 2-year Results from the LINKER-MM1 Phase 1/2 Clinical Trial
Clinical Lymphoma Myeloma & Leukemia · 2025
- Current and Future Directions of Immunotherapies in Multiple Myeloma
American Society of Clinical Oncology Educational Book · 2025
- The American Federation for Medical Research maintains commitment to decades of support of vaccine and vaccination research to improve public health
Journal of Investigative Medicine · 2025
- Second primary malignancy (SPM) in patients (pts) with multiple myeloma (MM) receiving chimeric antigen receptor T-cell (CAR T) therapy or other systemic anticancer therapy (SACT): A comparative study using a real-world database.
Journal of Clinical Oncology · 2025
- MagnetisMM-30: A phase 1b, open-label study of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma (RRMM).
Journal of Clinical Oncology · 2025
- Second primary malignancy in patients with diffuse large B-cell lymphoma (DLBCL) receiving chimeric antigen receptor T-cell (CAR T) therapy and other systemic anti-cancer therapy: A real-world data analysis.
Journal of Clinical Oncology · 2025
- SA25 Burden of Administration: Belantamab Mafodotin (Belamaf) Combinations vs Isatuximab (Isa) + Carfilzomib (K) + Dexamethasone (d), Daratumumab (D) + K + d, and K + d in Relapsed/Refractory Multiple Myeloma (RRMM)
Value in Health · 2025
- EE327 Belantamab Mafodotin, Pomalidomide, and Dexamethasone (BPd) in Relapsed/Refractory Multiple Myeloma (RRMM): Quality-Adjusted Life-Year (QALY) Results From a Cost-Effectiveness Model
Value in Health · 2025
- Talquetamab, a GPRC5D×CD3 bispecific antibody, in combination with pomalidomide in patients with Relapsed/Refractory multiple myeloma: Updated safety and efficacy results from the Phase 1b monumental-2 study
Blood · 2025
- Blood×34
- Clinical Lymphoma Myeloma & Leukemia×14
- Journal of Clinical Oncology×11
- Cancer Research×5
- HemaSphere×4
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 11, 2026.
Claim or correct this profile